Share Tool

Biotech Outlook Remains Strong Despite Recent Selloff 

John Schroer 

 

5/21/2014 

The recent biotech selloff has led to concerns about the sector’s health, but John Schroer, Sector Head of Health Care, thinks innovative companies will ultimately drive long-term earnings growth and share prices.
With the biotechnology sector experiencing strong overall performance in recent years, a recent selloff—albeit a mild one—has raised some concerns about the duration of this correction and the health of the sector.

Clearly, there are number of short-term reasons for the recent correction. Many companies had been trading at high valuation levels by historical standards, and there were near-record levels of initial public offerings and secondaries. In addition, speculation in earlier-stage and lesser-quality names had created greater near-term risk. Markets were unnerved by a letter from the US House of Representatives questioning the price of a new high-profile breakthrough drug, which raised the specter of price controls. All of these factors were then magnified by sector rotation away from high-growth names.

But we don’t view this as the end of a growth cycle for the biotechnology sector, or even another example of a typical “boom-and-bust” market. Instead, we believe we are witnessing a healthy correction that will provide significant long-term investment opportunities.

Our stock selection conviction is based on close analysis of underlying drivers. Unlike in past cycles, the sector’s recent strength has been driven not by profit-less technology platforms but by new therapeutic introductions resulting in significant revenues and earnings. Most importantly, we are witnessing ongoing innovation in the sector, with robust product pipelines addressing oncology, neurological disorders, infectious diseases and metabolic disorders.

As a result, we believe revenue and earnings growth rates for biotechnology companies should continue to outpace those of the broader market, driving biotechnology stock prices higher. Investors could use the correction as a buying opportunity, with many companies now trading in line with the market using a forward price-to-earnings metric.

We remain positive on the long-term potential of the biotechnology sector and believe that patient investors who use a disciplined investment process can outperform the broader market. Our investment process will continue to focus on companies with significant and innovative new therapeutics, which we believe will drive long-term earnings growth and ultimately share prices.




A Word About Risk: Investing involves risk and you can lose money. Equities have tended to be volatile and, unlike bonds, do not offer a fixed rate of return. Dividend-paying stocks are not guaranteed to continue to pay dividends. High-yield or “junk” bonds have lower credit ratings and involve a greater risk to principal. Investing in a limited number of issuers or sectors may increase risk and volatility.

The material contains the current opinions of the author, which are subject to change without notice. Statements concerning financial market trends are based on current market conditions, which will fluctuate. References to specific securities and issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Forecasts and estimates have certain inherent limitations, and are not intended to be relied upon as advice or interpreted as a recommendation.

 

Search

> Advanced Search

Find a Product

Or Select

Or Browse by

Contact Us

For all inquiries please contact us

Follow Us

       

Related Documents

TypeTitle
Allianz Global Investors Insights May 2014 
Investor
Market Insights 
AGI-2014-05-13-9728 

Share

Facebook
LinkedIn
Twitter

You are currently leaving us.allianzgi.com and navigating to a third-party website. Allianz Global Investors Distributors LLC accepts no responsibility for content on third-party sites or for the services provided. When using the services provided by a third-party site, you are subject to that site’s terms of service and privacy rules, which you should review carefully.